A Third Proof-of-Concept Study to Evaluate the Efficacy of NOBO, a Novel Postbiotic, in Controlling Axillary Odor in Healthy Adults | NCT07726238

NCT07726238

Overview

NCT ID: NCT07726238
Lead Sponsor: KingdomINDUSTRY
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Split-Axilla, Proof-of-Concept Study #3 to Evaluate the Efficacy of NOBO, a Novel Postbiotic, in Controlling Axillary Odor in Healthy Adults
Brief Summary: The goal of this clinical trial is to evaluate the performance of NOBO, a yeast-based fermentation product (postbiotic) designed to control axillary odor, in controlling axillary odor in healthy male and female adults age 18 - 70 with confirmed self-perception of body odor. The main question it aims to answer is: Does NOBO decrease self-perceived odor of the intervention axilla compared to the placebo axilla at any time point? Researchers will compare the intervention axilla odor score to the placebo axilla odor score to see if there is a difference in self-perceived odor. Participants will:

be given a NOBO deodorant spray and a placebo deodorant spray (each assigned to one axilla)

self assess body odor

self assess skin irritation
Conditions

Status and Timeline

Status: Active, not recruiting
Last Update Posted: Jul 31, 2026Actual
Start Date: Jul 27, 2026Actual
Primary Completion Date: Jul 31, 2026Actual
Completion Date

Participation Criteria

Ages Eligible for Study: Adult (18-64)Older Adult (65+)
Sexes Eligible for Study: All
Accepts Healthy Volunteers?: Yes
Eligibility Criteria: Inclusion Criteria:

Age: The subject is an adult between 18 and 70 y.o.

Skin health: The subject has no active skin conditions or lesions in the axillary region and no existing skin conditions (e.g., eczema, psoriasis, contact dermatitis).

Skin allergies: The subject has no known allergies to skin treatment products or cosmetics, toiletries, and/or topical drugs.

Exclusion Criteria:

Subject is pregnant, nursing, or planning to become pregnant in the next 6 months.

Subject is an insulin-dependent diabetic.

Subject has been diagnosed or treated for cancer in the past 5 years.

Subject is currently using or has not used in the past two weeks any systemic antibiotics.

Subject is currently using or used within the last month any topical medications, over-the-counter (OTC) or prescription products on the underarms.

Subject is currently taking or plans to take during the study any anti-inflammatory for a chronic condition (except 81 mg-Aspirin per day), immunosuppressant, antihistamine, or sedative medications (i.e. containing antihistamines like Tylenol PM, Nyquil, etc.).

Subject is currently participating in another underarm clinical trial. Subjects may participate in other studies as long as the same test sites are not used or are testing similar products.

Study Plan

Study Type: Interventional
Phase: Not Applicable
Enrollment: 14Estimated
Primary Purpose: Treatment
Allocation: Randomized
Interventional Model: Parallel Assignment
Masking: Triple

Contacts and Locations

Central Contacts: No data available
Locations: Kingdom

Similar Studies

Participant Group/Arms

NOBO deodorantExperimental

The NOBO deodorant is composed of ≤2.6% yeast fermentation product and 10% ethanol in water. A dose is 0.48 mL per axilla for female subjects (3 actuations) or 0.64 mL per axilla for male subjects (4 actuations), delivered twice a day.

Other: NOBO postbiotic

Placebo deodorantPlacebo Comparator

The placebo deodorant is composed of 10% ethanol in water. The placebo deodorant contains the same concentration of ethanol as the NOBO deodorant. A dose is 0.48 mL per axilla for female subjects (3 actuations) or 0.64 mL per axilla for male subjects (4 actuations), delivered twice a day.

Other: Placebo